Proprietary GEP Test Portfolio: Castle Biosciences specializes in advanced, proprietary gene expression profile (GEP) tests, such as DecisionDx-Melanoma and DecisionDx-SCC, which provide prognostic information beyond traditional pathology and help guide patient management in skin cancers.

Robust Clinical Validation: The company invests heavily in clinical research, resulting in extensive peer-reviewed publications and data demonstrating the clinical utility and analytical validity of its tests, which supports physician adoption and payer coverage.

Niche Market Leadership: Castle Biosciences has established a dominant position in specific segments of dermatologic oncology diagnostics, particularly for risk stratification in melanoma and squamous cell carcinoma, becoming a leading provider for these specialized tests.